

研究成果の刊行に関する一覧表(平成 25 年度)

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, <u>Tanaka Y.</u>	The JAK inhibitor tofacitinib reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.	Ann Rheum Dis	in press		
<u>Tanaka Y.</u> , Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, Nakano K, Nakayamada S, Yamaoka K, Sawamura F, Saito K.	Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.	Ann Rheum Dis	in press		
<u>Tanaka Y.</u>	Next stage of RA treatment: TNF-inhibitor-free remission will be a possible treatment goal ?	Ann Rheum Dis	72	ii124-ii127	2013
<u>Tanaka Y.</u> , Maeshima Y, Yamaoaka K.	In vitro and in vivo analysis of a Jak inhibitor in rheumatoid arthritis.	Ann Rheum Dis	71	i70-i74	2012
Iwata S, Yamaoka K, Niuro H, Nakano K, Wang S-P, Akashi K, <u>Tanaka Y.</u>	Amplification of toll-like receptor-mediated signaling through Syk in human B cell activation.	J Allergy Clin Immunol	129	1594-1601	2012
Koike T.	IgG4-related disease: why high IgG4 and fibrosis.	Arthritis Res Ther	15(1)	103	2013
Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Hartmut K, Vipin A, and <u>Tanaka Y.</u>	Adalimumab, a Human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early RA; the HOPEFUL 1 study.	Ann Rheum Dis	in press		

Katayama M, Ohmura K, Yukawa N, Terao C, Hashimoto M, Yoshifuji H, Kawabata D, Fujii T, Iwakura Y, Mimori T	Neutrophils are essential as a source of IL-17 in the effector phase of arthritis.	PLoS One	8(5)	e62231	2013
Terao C, Hashimoto M, Yamamoto K, Murakami K, Ohmura K, Nakashima R, Yamakawa N, Yoshifuji H, Yukawa N, Kawabata D, Usui T, Yoshitomi H, Furu M, Yamada R, Matsuda F, Ito H, Fujii T, Mimori T	Three Groups in the 28 Joints for Rheumatoid Arthritis Synovitis - Analysis Using More than 17,000 Assessments in the KURAMA Database.	PLoS One	8(3)	e59341	2013
Sumitomo S, Fujio K, Okamura T, Morita K, Ishigaki K, Suzukawa K, Kanaya K, Kondo K, Yamasoba T, Furukawa A, Kitahara N, Shoda H, Shibuya M, Okamoto A, Yamamoto K.	Transcription factor early growth response 3 is associated with the TGF- β 1 expression and the regulatory activity of CD4-positive T cells in vivo.	J Immunol	191(5)	2351-9	2013
Iwasaki Y, Fujio K, Okamura T, Yanai A, Sumitomo S, Shoda H, Tamura T, Yoshida H, Charnay P, Yamamoto K	Egr-2 transcription factor is required for Blimp-1-mediated IL-10 production in IL-27-stimulated CD4+ T cells.	Eur J Immunol	43(4)	1063-73	2013
Kawashiri SY, Arima K, Suzuki T, Nakashima Y, Horai Y, Okada A, Tamai M, Nakamura H, <u>Kawakami A.</u>	Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate	Mod Rheumatol	in press		
Kawashiri SY, Fujikawa K, Nishino A, Suzuki T, Okada A, Nakamura H, <u>Kawakami A.</u>	Usefulness of ultrasonography-proven tenosynovitis to monitor disease activity of a patient with very early rheumatoid arthritis treated by abatacept.	Mod Rheumatol	23(3)	582-586	2013

Kita J, Tamai M, Arima K, Kawashiri SY, Horai Y, Iwamoto N, Okada A, Koga T, Nakashima Y, Suzuki T, Yamasaki S, Nakamura H, Origuchi T, Ida H, Aoyagi K, Uetani M, Eguchi K, <u>Kawakami A</u> .	Significant improvement in MRI-proven bone edema is associated with protection from structural damage in very early RA patients managed using the tight control approach.	Mod Rheumatol	23(2)	254-259	2013
Satomura K, Torigoshi T, Koga T, Maeda Y, Izumi Y, Jiuchi Y, Miyashita T, Yamasaki S, <u>Kawakami A</u> , Aiba Y, Nakamura M, Komori A, Sato J, Ishibashi H, Motokawa S, Migita K.	Serum amyloid A (SAA) induces pentraxin 3 (PTX3) production in rheumatoid synoviocytes.	Mod Rheumatol	23(1)	28-35	2013
玉井慎美, <u>川上 純</u> .	MRI 画像の特徴と早期診断・治療評価.	Mebio	30(2)	16-20	2013
Ikeda K, Seto Y, Narita A, kawakami A, Kawahito Y, Ito H, Matsushita I, Ohno S, Nishida K, Suzuki T, Kaneko A, Ogasawara M, Fukae J, Henmi M, Sumida T, Kamishima T, <u>Koike T</u> .	Ultrasound assessment of synovial pathologic features in rheumatoid arthritis using comprehensive multi-plane images of the 2nd metacarpophalangeal joint - Identification of the components which are reliable and influential on the global assessment of the whole joint.	Arthritis Rheum	in press		
Takamura A, Hirata S, Nagasawa H, Kameda H, Seto Y, Atsumi T, Dohi M, <u>Koike T</u> , Miyasaka N, Harigai M.	A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology.	Mod Rheumatol	23(2)	297-303	2013
<u>上阪 等</u>	関節リウマチ制圧に向けた新しい抗リウマチ薬の発見	お茶の水医学雑誌	61	385-393	2013

<p>Gazal S, Sacre K, Allanore Y, Teruel M, Goodall AH, Tohma S, Alfredsson L, Okada Y, Xie G, Constantin A, Balsa A, Kawasaki A, Nicaise P, Amos C, Rodriguez-Rodriguez L, Chiocchia G, Boileau C, Zhang J, Vittecoq O, Barnetche T, Gonzalez-Gay MA, Furukawa H, Cantagrel A, Le Loet X, Sumida T, Hurtado-Nedelec M, Richez C, Chollet-Martin S, Schaefferbeke T, Combe B, Khoryati L, Coustet B, El-Benna J, Siminovitch K, Plenge R, Padyukov L, Martin J, Tsuchiya N, Dieud P.</p>	<p>Validation of EULAR primary Sjogren's Syndrome disease activity and patient indexes.</p>	<p>Ann Rheum Dis</p>	<p>in press</p>		
<p>Yoon J, Sudo K, Han J, Chae M, Park S, Weinstein M, Nakae S, Yamashita T, Lee , <u>Sumida T</u>, Kuroda M, Mamura M.</p>	<p>Smad2 is the TGF-receptor-regulated Smad to suppress the immunogenicity of mouse and human dendritic cells.</p>	<p>Eur J Immunol</p>	<p>in press</p>		
<p>Yoon JH, Jung SM, Park SH, Kato M, Yamashita T, Lee IK, Sudo K, Nakae S, Han JS, Kim OH, Oh BC, <u>Sumida T</u>, Kuroda M, Ju JH, Jung KC, Park SH, Kim DK, Mamura M.</p>	<p>Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes.</p>	<p>EMBO Mol Med</p>	<p>5</p>	<p>1720-39</p>	<p>2013</p>
<p>Umeda N, Matsumoto I, Ito I, Kawasaki A, Tanaka Y, Inoue A, Tanaka Y, Tsuboi H, Suzuki T, Hayashi T, Ito S, Tsuchiya N, <u>Sumida T</u>.</p>	<p>Anti-citrullinated glucose-6-phosphate isomerase peptide antibodies in patients with rheumatoid arthritis are associated with HLA-DRB1 shared epitope alleles and disease activity.</p>	<p>Clin Exp Immunol</p>	<p>172</p>	<p>44-53</p>	<p>2013</p>
<p>Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, <u>Sumida T</u>.</p>	<p>Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor inhibitors: One year follow-up by low-field extremity MRI.</p>	<p>Mod Rheumatol</p>	<p>23</p>	<p>782-7</p>	<p>2013</p>

Nishimoto N, Koichi Amano, <u>Tsutomu Takeuchi</u> , Nobuhiro Takagi, et al.	Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.	Mod Rheumatol	24	26-32	2014
Kaneko Y, Kondo H and <u>Takeuchi T.</u>	ACR/EULAR remission criteria maintains strict performance when evaluated in 44 joints.	J Rheumatology	40	1254-8	2013
Nishina N, Kaneko Y, Kameda H, Kuwana M, and <u>Takeuchi T.</u>	Reduction of plasma IL-6, but not TNF- α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression.	Clinical Rheumatol	32	1661-7	2013
<u>Takeuchi T.</u> , Tanaka Y, Yamanaka H,T, Baker D, and the GO-MONO study group. Et al.	Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying anti-rheumatic drugs: results of the Phase 2/3, multicenter, randomized, double-blind, placebo-controlled GO-MONO study through 24 weeks.	Ann Rheum Dis	72	1488-95	2013
Nishina N, Kikuchi J, Hashizume M, Yoshimoto K, Kameda H, and <u>Takeuchi T.</u>	Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy.	Ann Rheum Dis	in press		
Nakashima R, Imura Y, Hosono Y, Seto M, Murakami A, Watanabe K, Handa T, Mishima M, Hirakata M, Takeuchi T, Fujio K, Yamamoto K, Kohsaka H, Takasaki Y, Enomoto N, Suda T, Chida K, Hisata S, Nukiwa T, <u>Mimori T.</u>	The Multicenter Study of a New Assay for Simultaneous Detection of Multiple Anti-Aminoacyl-tRNA Synthetases in Myositis and Interstitial Pneumonia	PLoS One	9	e85062	2014

<p>Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedrén S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, <u>Mimori T</u>, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak PP, Crusius JB, van der Horst-Bruinsma IE, Wolbink GJ, van Riel PL, van de Laar M, Guchelaar HJ, Shadick NA, Allaart CF, Huizinga TW, Toes RE, Kimberly RP, Bridges SL Jr, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJ, Karlson EW, Plenge RM.</p>	<p>Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis.</p>	<p>PLoS Genet</p>	<p>9</p>	<p>e1003394</p>	<p>2013</p>
<p>Terao C, Ohmura K, Kawaguchi Y, Nishimoto T, Kawasaki A, Takehara K, Furukawa H, Kochi Y, Ota Y, Ikari K, Sato S, Tohma S, Yamada R, Yamamoto K, Kubo M, Yamanaka H, Kuwana M, Tsuchiya N, Matsuda F, <u>Mimori T</u>.</p>	<p>PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population.</p>	<p>Arthritis Rheum</p>	<p>65</p>	<p>472-80</p>	<p>2013</p>
<p>Tsuboi H, Hagiwara S, Asashima H, Umehara H, Kawakami A, Nakamura H, Sano H, Tsubota K, Ogawa Y, Takamura E, Saito I, Inoue H, Nakamura S, Moriyama M, Takeuchi T, Tanaka Y, Hirata S, <u>Mimori T</u>, Matsumoto I, Sumida T.</p>	<p>Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients.</p>	<p>Mod Rheumatol</p>	<p>23</p>	<p>219-25</p>	<p>2013</p>
<p>Terao C, Hashimoto M, Yamamoto K, Murakami K, Ohmura K, Nakashima R, Yamakawa N, Yoshifuji H, Yukawa N, Kawabata D, Usui T, Yoshitomi H, Furu M, Yamada R, Matsuda F, Ito H, Fujii T, <u>Mimori T</u>.</p>	<p>Three Groups in the 28 Joints for Rheumatoid Arthritis Synovitis - Analysis Using More than 17,000 Assessments in the KURAMA Database.</p>	<p>PLoS One</p>	<p>8</p>	<p>e59341</p>	<p>2013</p>

Yoshida S, Ikari K, Yano K, Toyama Y, Taniguchi A, <u>Yamanaka H</u> , Momohara S.	Lack of association between IL-15 genetic variants and progression of joint destruction in Japanese patients with rheumatoid arthritis.	Ann Rheum	in press		
Suzuki T, Ikari K, Yano K, Inoue E, Toyama Y, Taniguchi A, <u>Yamanaka H</u> , Momohara S.	PADI4 and HLA-DRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study.	Plos One	in press		
Seto Y, Inoue E, Shidara K, Hoshi D, Sugimoto N, Sato E, Tanaka E, Nakajima A, Taniguchi A, Momohara S, <u>Yamanaka H</u> .	Functional disability can deteriorate despite suppression of disease activity in patients with rheumatoid arthritis: a large observational cohort study.	Mod Rheumatol	23	1179-85	2013
<u>Yamanaka H</u> , Seto Y, Tanaka E, Furuya T, Nakajima A, Ikari K, Taniguchi A, Momohara S.	Management of rheumatoid arthritis: the 2012 perspective	Mod Rheumatol	23	1-7	2013
Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyster AE, Greenberg JD, Kremer JM, Pappas DA, Jiang L, Yin J, Ye L, Su DF, Yang J, Xie G, Keystone E, Westra HJ, Esko T, Metspalu A, Zhou X, Gupta N, Mirel D, Stahl EA, Diogo D, Cui J, Liao K, Guo MH, Myouzen K, Kawaguchi T, Coenen MJ, van Riel PL, van de Laar MA, Guchelaar HJ, Huizinga TW, Dieudé P, Mariette X, Louis Bridges Jr S, Zhernakova A, Toes RE, Tak PP, Miceli-Richard C, Bang SY, Lee HS, Martin J, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Rantapää-Dahlqvist S, Arlestig L, Choi HK, Kamatani Y, Galan P,	Genetics of rheumatoid arthritis contributes to biology and drug discovery.	Nature	506	376-381	2013

<p>Lathrop M; the RACI consortium; the GARNET consortium, Eyre S, Bowes J, Barton A, de Vries N, Moreland LW, Criswell LA, Karlson EW, Taniguchi A, Yamada R, Kubo M, Liu JS, Bae SC, Worthington J, Padyukov L, Klareskog L, Gregersen PK, Raychaudhuri S, Stranger BE, De Jager PL, Franke L, Visscher PM, Brown MA, <u>Yamanaka H</u>, Mimori T, Takahashi A, Xu H, Behrens TW, Siminovitch KA, Momohara S, Matsuda F, <u>Yamamoto K</u>, Plenge RM.</p>					
<p>Iwasaki Y, Fujio K, Okamura T, Yanai A, Sumitomo S, Shoda H, Tamura T, Yoshida H, Charnay P, <u>Yamamoto K</u>.</p>	<p>Egr-2 transcription factor is required for Blimp-1-mediated IL-10 production in IL-27-stimulated CD4+ T cells.</p>	<p>Eur J Immunol</p>	<p>43</p>	<p>1063-73</p>	<p>2013</p>

研究成果の刊行に関する一覧表(平成 25 年度)

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	出版社名	出版年
		書籍名	出版地	ページ
三森経世	ステロイド	郡義明	文光堂	2013
		基本薬の選び方と使い方のコツ	東京	267-277
三森経世	筋炎における自己抗体	鈴木則宏	中外医学社	2014
		神経	東京	245-252